Aethlon Medical (AEMD) 10 Aug 222023 Q1 Earnings call transcript

Hello, and welcome to the Aethlon First Quarter Fiscal 2023 Earnings and Corporate Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please note this event is being recorded. to conference like Frakes, to now CFO. would turn over the Jim I go Please ahead.

and everyone. financial XXXX. is good Medical’s operator, today, June Officer. you, Thank afternoon, XX, Eastern pm its earnings I’m Chief Time call. first At and ended X:XX first Medical Welcome conference My for Frakes, name released Jim Aethlon Aethlon’s Financial results quarter Aethlon to quarter

Aethlon Medical’s page If earnings please or you have Investors not visit at received www.aethlonmedical.com. seen the release,

the and Dr. our Medical Dr. introduction financials. Following and our CEO, then I and an of Officer, recent this statement, Aethlon’s provide will Aethlon’s strategy make reading Chuck forward-looking Science of will Fisher; Chief Aethlon’s some Steven developments. on overview brief and LaRosa, Chief remarks

the the for then We Q&A up will open session. call

reflect statement the and Securities Before is contain this and to cautions the Securities XXXX over release The XX-K statement filings amended. fiscal on and please that Act ended the forward-looking Risk the Company’s of our the not to you Dr. of call caption Commission. call news Exchange to Form Fisher, it nor the Dr. Company materially XXXX, on that expectations does a annual the note that update could statements can events meaning the Aethlon’s call does Chief of any that, of I report for I Exchange forward-looking Company’s turn those any in actual intend, amended, recent hand Act Securities that XXXX required year results today the as assumptions forward-looking or within historical cause over Factors statements Executive Factors not to found Fisher, are statements date the statement. the as the now under statements. other a significant Such may Company and will subject results XX-Q the XX, materially differ Form call. be with this forward-looking from and this of March With Except most conference duty as as results in differ in information based anticipated to future Officer. are to circumstances. law, undertake fact in These statements anticipated and the forward-looking risks report be the of on by may is and Chuck uncertainties, from

Aethlon. and all dialing thanks Thank a it's in. Fisher, you weeks. Chuck been call, last call last -- Jim, and June our six been is busy you, XX, of its busy My since joining Since of and on I’m six name our CEO weeks

for and The may XX, on capture to be should the Before tested. Resin I Affinity clinical hand update the peer-reviewed Viral manuscript some affinity Relevant to the Dr. remarks and COVID-XX call and in demonstrating "Removal variants. Officer, of efficiency oncology. who Hemopurifier, XX% proprietary vitro, monkeypox. recent to and will an infection, ONE that Galanthus PLOS July resin infectious our an Steven Medical developments LaRosa, variants about recently SARS-CoV-X to was able published variants Omicron future including Chief published key the in in component Containing Scientific with bind Chief trials affinity range SARS-CoV-X GNA that that arise. was SARS-CoV-X Clinically brief Hemopurifier all from diseases Delta by Aethlon’s XXXX. findings provide from XX% a potentially bind Agglutinin" suggests manuscript the over paper and variants I'd is like a to of in titled clinically GNA Nivalis We Aethlon’s relevant make seven resin, this The and on variants able a

Hemopurifier's of that Hemopurifier removed bound that the we the vitro current monkeypox an binding current the the In strain effectively we the strain amount viral strain demonstrated experiment virus. the mutations virus, the new a that captures find envelope, with commissioning of and Given monkeypox not sugars believe which the change do confirm We are recognized Hemopurifier the in XXXX, ability in current that be to ongoing of virus. by present monkeypox the to in-vitro in the Hemopurifier. affected should because the conducted in not outbreak study is effectively GNA

the hour XX first testing, This culture we For provided study more in context after fluids using regarding hours monkeypox The mil, run a studies a The Battelle per of our to and high Hemopurifier that monkeypox the miniature study of Memorial circulated through XX,XXX of GPUs monkeypox in concentrations by data when testing. XX% was were vitro the depleted Hemopurifier. of polymerase virus, after PCR. testing, from six XX% and the Hemopurifier. XX% conducted of commissioned cell the removed verification or XXXX indicated study of were time, virus triplicate chain reaction, study, demonstrated in version approximately real hours Institute rapidly

continue and monkeypox monitor We severity. to caseload disease virus

We We emergency. FDA, made. single use, Human to past physicians we yet us pre-emergency done not monkeypox, declaration emergency have to in with to On the Emergency be SARS-CoV-X. and not been the and the this occur. August process U.S. prepared which a or patient the requesting FDA officially Use to to Health An contacted DHHS dissimilar confirm health the as Services, Hemopurifier the Department plan declaration provide of the X, by declared we've does XXXX, could in package what submit event so authorization a has

Scientific Now, call to and Steve? Chief let our the MD, turn me Steven over Chief LaRosa, Officer Medical Officer.

at the to and LaRosa, for our Chief Steven Officer thanks and Aethlon. everyone, listening Scientific Medical Chief presentation. in I'm Dr. Hi,

the for the We exemption under our known threatening the investigational Hemopurifier an update, for patient open continue last our infections. first device has severe life our clinical advance to completed COVID-XX study. trial as Since IDE viral

feasibility the improve trial approved actively to a are the at eliminated Medicity patients On newly the trial COVID-XX screening. time in expect in new Administration continue protocol Drug supplement contract supplement patient to has catheter continues Boards, approvals and actively a criteria our inclusion Delhi Institutional July with of their have clinical tolerated in of place screen of Our X in this This organization, approved Food India our Hospital, that and study. have and along screen active to US patients. patients must Review should change have September the sites currently In COVID-XX multi-specialty Medanta August we and dialysis submitting to a this dialysis sites This IRBs supplement patients our enrolled in one and previously in research The hospital XXXX, to protocol. India, our year. PPD. enrolling

additional in trial is and has assessing Qualtran identified potential sites CRO, currently Our the for LLC India feasibility.

head neck In COVID-XX, IDE cancer. screen work to with continue and addition to for our trial we in clinical our patients

have We request trial. is If to FDA, this the a it by the for supplement change of the protocol the inclusion who patients increase to in population chemotherapy the submitted accepted have study. eligible would platinum FDA failed the

We over will protocol new despite of trial us now the are allow two effects call turn also a would back therapy. to a period previous I to month checkpoint progressed, tumor the of a the for drafting currently inhibitor cancer Hemopurifier examine that types Frakes. multiple has clinical Jim the where in

XXXX, have At June Thanks, cash everyone. approximately XX, million. of balance afternoon a $XX.X again Steve, we and good

June in $X.XX ended million ended XX, XXXX. compared general our consolidated And expenses increase XXXX contract our expense June regulatory The due fees were and fees was XXXX associated then the approximately payroll increase and administrative $XXX,XXX. payroll $XX,XXX for and our in the stock XXXX approximately of $XX,XXX of labor our our approximately $XXX,XXX quarter Our strategy our with professional million in $XX,XXX. increase $XXX,XXX operating due $X.XX the development increase $XXX,XXX three a the in in a a in due to The increase with an expenses, associated in supplies, services. $XXX,XXX to compensation and or of the increase was three $XXX,XXX clinic in professional of combination our fees was our months insurance our in a expenses $XX,XXX professional expense approximately approximately related and expenses Jun increase This our and months increase analytical A XX, $XX,XXX primarily services, to increase and of to $XX,XXX. increase increase increases to $XX,XXX XX% product due the for was in in expenses and primarily of period of combination based related in general rent expenses administrative trial our XX, expense expense. $XXX,XXX a in a

ended June did XX not and related paid bonus those $XXX,XXX, our NIH the expense compensation decreased XXXX a any those to achieving received contractual XX, primarily government related the in based period ended certain contracts revenue XX, deferred in certain achieving XXXX and $XXX,XXX XXXX. there the contracts of Jim $XXX,XXX in with in milestones months of XXXX as the period. cash had three were by approximately CEO June XXXX a And revenue as compared June employment We in agreement out not because bonuses our to months for Our June milestones to result the we the three no record approximately $XX,XXX, contracts.

payments the did those we the However, and from amounts receive government.

three three from in $X.X interests our result noted, approximately approximately months XX, ended June June revenues $X.X the and increased million loss controlling the a changes before to expenses months XXXX, XXXX. of the just non for As the for net I million XX, ended

net to under months In million During or ATM approximately sales our we agreement ended XXXX sales stock. the with through common pursuant date, of ATM common June and raised XX, agreements to HC our we raised and approximately our $XXX,XXX August stock. $X.X proceeds three July under Co, XXXX, in Wainwright

LaRosa cash our files, position We of months issued for earnings earlier release a and That these our plans June for current afternoon. release for operations the those ended trials. well the very and of this related just and results clinical and statements commentary for three conducting XX, XX, sets XXXX Hemopurifier and sheet noted, up press as XXXX. the XXXX, us included manufacturing balance June included for the Steve Our

call. We will XX-Q file following a form quarterly report this on

fiscal Our next for earnings will any I quarterly the early second form in questions. XX, now September Chuck, our with be call have. ending XX-Q XXXX open questions on quarter to you November. happy call please would filing for may take of that report Operator, Steve coincide the the and And

you. Thank

session. comes go Instructions] today answer Please and question Marla [Operator the begin Our ahead. now from Zacks. question first Marin will of We

given the where we Thank the what TDCL given us? with we've think than the and of I kind Have the cautious probably you. Hemopurifier One questions. given any regulator's, have inquiries few virus incoming now right can experienced towards over informal more share had regarding including how, that people being years. you is two you I not past leaning on are that monkeypox the

Yes. Hi. Thanks, Marla.

from specific for monkeypox inquiries specific received date. physicians about We the not have Hemopurifier to

But, of of study, going you're back virus? XXXX to you, the confident Okay. treatment in regarding about terms the Hemopurifier efficacy the this

is which that data removed we the Well, so what monkeypox affinity completely Hemopurifier, system, don't system. version in know can is At small data and rapidly our that humans today. extrapolate a in uses of resin, vitro this we point, We that effectively the humans. in that in same to effects have very

Can might of then, Jim. other your talk sustaining we impact inflationary to cash start be wage for able and And as one a have pressure Okay. might inflation about studies will that upward research before any thinking current I be that long alternatives? we balance result continue seeing about other potential This is how question. you pressures

the impact we've don't -- inflationary I felt inflationary pressure. of current think

costs supplies Marla. go I that have up various of don't our materially any assume employee impacting but may slightly, Some I cash would see up. gone runway, is

you. Thank Okay.

impact, significant but way, an material. not obviously, incremental bit overall, little every In could a it's have

Thank great. you. Okay,

Marla. Thanks,

Thanks Marla.

This turn concludes session. CEO would and Chuck the question like to closing I for remarks. back to conference over answer Fisher, the

results. to Thank joining on And calling forward us to you date to keeping thank quarter today our you up all first in. for you again future discuss calls. for look We'll

Thank is for conference you The concluded. your now participation.

You may now disconnect.